Single Session Combined Locoregional Therapies for Hepatocellular Carcinoma
NCT ID: NCT02646137
Last Updated: 2018-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
50 participants
INTERVENTIONAL
2015-01-31
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma
NCT02729506
Combined Therapy for Hepatocellular Carcinoma >3-<5 cm
NCT04721470
Sequential Treatment of Hepatocellular Carcinoma by Transarterial Chemoembolization and Local Ablation or External Radiation
NCT04813861
RCT of TAE Simultaneously Combined Thermal Ablation for Large Hepatocellular Carcinoma
NCT02964260
TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular Carcinoma
NCT00556803
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Transarterial chemoembolization (TACE)
treated by transarterial chemoembolization
Transarterial chemoembolization (TACE)
TACE exploits the preferential hepatic arterial supply of liver tumors for targeted delivery of chemotherapeutic agents followed by embolization or reduction in arterial flow using various types of particles
Radiofrequency ablation with TACE
Radiofrequency ablation combined with TACE
Radiofrequency ablation combined with TACE
Radiofrequency ablation (RFA) is an alternative therapy for HCC and liver metastases that can destroy a tumor by inducing thermal injury to the tissue through electromagnetic energy deposition
Microwave ablation combined with TACE
Microwave ablation combined with TACE.
Microwave ablation combined with TACE
Microwave ablation (MWA) is an appealing alternative therapy for HCC in which a microwave antenna is placed directly into the tumor, emitting an electromagnetic wave which agitates water molecules in the surrounding tissue, producing friction and heat, thereby inducing cell death via coagulation necrosis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transarterial chemoembolization (TACE)
TACE exploits the preferential hepatic arterial supply of liver tumors for targeted delivery of chemotherapeutic agents followed by embolization or reduction in arterial flow using various types of particles
Radiofrequency ablation combined with TACE
Radiofrequency ablation (RFA) is an alternative therapy for HCC and liver metastases that can destroy a tumor by inducing thermal injury to the tissue through electromagnetic energy deposition
Microwave ablation combined with TACE
Microwave ablation (MWA) is an appealing alternative therapy for HCC in which a microwave antenna is placed directly into the tumor, emitting an electromagnetic wave which agitates water molecules in the surrounding tissue, producing friction and heat, thereby inducing cell death via coagulation necrosis
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* serum albumin ≥ 3 gm/L.
* serum bilirubin \< 2.5 mg/dL.
* platelet count ≥70,000 mm3.
* INR ≤ 1.6.
* serum creatinine \< 2 mg/dl.
* tumor size more than 4 cm and confined to one lobe of the liver.
Exclusion Criteria
* A technically inaccessible hepatic artery.
* Metastatic HCC.
* More than three lesions.
* lesions in close proximity to the portal vein (PV),inferior vena cava (IVC) or gall bladder were excluded from the study.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Sherief Abd-Elsalam
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sherief Abd-Elsalam
Consultant liver and GIT diseases- Tanta university hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Elshazly Sheta, Professor
Role: PRINCIPAL_INVESTIGATOR
Hepatology and gastroenterology dept.-Tanta
Ferial El-kalla, Professor
Role: PRINCIPAL_INVESTIGATOR
Division of Gastroenterology and Hepatology- Tanta
Mohamed Elgharib, Professor
Role: STUDY_DIRECTOR
Interventional radiology - Ainshams university- Egypt
Abdelrahman kobtan, Consultant
Role: STUDY_CHAIR
liver diseases dept.-Tanta university hospital
Mohamed Elhendawy, Consultant
Role: STUDY_CHAIR
liver diseases dept.-Tanta university hospital
Sherief Abd-Elsalam, Consultant
Role: STUDY_CHAIR
Hepatology and gastroenterology dept.-Tanta
Ibrahim Amer, Consultant
Role: STUDY_CHAIR
Liver diseases and gastroenterology dept.-Tanta university hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tanta university hospital
Tanta, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Combined TACE and RF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.